Cetera Investment Advisers Boosts Holdings in Veru Inc. (NASDAQ:VERU)

Cetera Investment Advisers increased its stake in shares of Veru Inc. (NASDAQ:VERU) by 26.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 95,210 shares of the company’s stock after buying an additional 19,724 shares during the period. Cetera Investment Advisers owned about 0.07% of Veru worth $62,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in Veru by 37.1% during the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock worth $49,000 after purchasing an additional 20,430 shares during the period. Integrated Wealth Concepts LLC boosted its position in Veru by 31.3% during the fourth quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock worth $56,000 after purchasing an additional 20,500 shares during the period. Gladstone Institutional Advisory LLC boosted its position in Veru by 52.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock worth $57,000 after purchasing an additional 30,000 shares during the period. NewEdge Advisors LLC boosted its position in shares of Veru by 2,500.0% in the fourth quarter. NewEdge Advisors LLC now owns 130,000 shares of the company’s stock valued at $85,000 after acquiring an additional 125,000 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Veru by 35.2% in the fourth quarter. Jane Street Group LLC now owns 130,406 shares of the company’s stock valued at $85,000 after acquiring an additional 33,952 shares during the period. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Trading Up 13.6%

VERU stock opened at $0.58 on Tuesday. The firm has a 50 day moving average of $0.53 and a 200-day moving average of $0.61. Veru Inc. has a 12 month low of $0.45 and a 12 month high of $1.42. The firm has a market capitalization of $84.59 million, a P/E ratio of -2.22 and a beta of -0.74.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. Sell-side analysts predict that Veru Inc. will post -0.22 EPS for the current year.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.